Pharmaceutical

Novo faces growth challenges despite GLP-1 receptor agonist obesity boom

The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.

Aug 1, 2024 - 04:00
Novo faces growth challenges despite GLP-1 receptor agonist obesity boom
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
Read the original article

Tags:

Previous Article

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

Next Article

Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FDA-Approved Treatment for ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharma industry showers House GOP doctor with campaign cash

STAT+: Pharma industry showers House GOP doctor with ca...

Aug 3, 2023

STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers

STAT+: Inside Vertex’s decades-long quest to develop a ...

Dec 11, 2023

STAT+: An innovative eye stem cell transplant could help restore vision in people with chemical injuries

STAT+: An innovative eye stem cell transplant could hel...

Aug 19, 2023